VX-006 + Montanide ISA51

VX-006 + Montanide ISA51 is an **experimental therapeutic cancer vaccine formulation** composed of the synthetic peptide **VX-006** emulsified in the immunological adjuvant **Montanide ISA51**. - **VX-006** is a 27-amino acid synthetic polypeptide (sequence: YLQVNSLQTVYLEYRQVPVYLEEITGYL) that incorporates three optimized cryptic CTL epitopes derived from universal tumor antigens: telomerase reverse transcriptase (hTERT), MAGE-A2, and HER-2/neu. - The vaccine is designed to elicit polyspecific cytotoxic T lymphocyte responses against multiple tumor antigens, potentially enhancing anti-tumor immunity in a broad range of cancers as almost all tumors express at least one included antigen[1]. - **Montanide ISA51** is a highly purified mineral oil adjuvant (with surfactant Mannide monooleate), generating a water-in-oil emulsion for depot effect, increasing both CD4+ and CD8+ T-cell and antibody responses, and enhancing immune response magnitude and duration[1][2][5]. - Developed for injectable use, this formulation is under clinical investigation (preclinical and/or early clinical stages) for use as a therapeutic cancer vaccine, especially for solid tumors[1].

Other names

Vx006 polypeptide emulsified in Montanide ISA51Vx-006 polypeptide emulsified in Montanide ISA51Vx 006 polypeptide emulsified in Montanide ISA51